NNT and prostate carcinoma: Higher expression (95% CI HR > 1) of CACNA1G-AS1, F11-AS1, and NNT-AS1 were found to significantly lower the overall survival rates of the patients with Prostate cancer than those of patients with lower expression of these DElncRNAs (Figs. 5 and 6).